Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Duke University |
---|---|
Information provided by: | Duke University |
ClinicalTrials.gov Identifier: | NCT00606437 |
Results to date of umbilical cord blood transplantation in adult and fully mature adolescent patients are inferior to what is seen in children, due to a lower stem cell dosage in adults and a more toxic conditioning regimen. This phase 1 protocol will use a potentially less toxic bone marrow conditioning regimen, followed by infusion of a combined umbilical cord blood graft that will provide the patient with a higher stem cell dose than can be given with a single umbilical cord blood infusion. The subjects will be conditioned with a total body irradiation (TBI) 13.5 Gy and fludarabine. Following conditioning, up to two unrelated, partially matched umbilical cord blood grafts will be infused that will provide a minimum nucleated cell dose of 3 x 10e7/kg . The primary objective of this study is to measure the frequency of treatment-related toxicity and engraftment.
Condition | Intervention | Phase |
---|---|---|
Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors Hodgkin's Disease Myelofibrosis |
Procedure: Total Body Irradiation with Fludarabine in UCB Transplants |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts |
Estimated Enrollment: | 24 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Experimental
Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
|
Procedure: Total Body Irradiation with Fludarabine in UCB Transplants
Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
|
Results to date of umbilical cord blood transplantation in adult and fully mature adolescent patients are inferior to what is seen in children. There are two reasons for this. First is that the stem cell dose, measured in nucleated cells/kg body weight, is considerably lower due to the size of the recipient. This results in a higher incidence of graft failure, delayed engraftment, and impaired immune reconstitution. Multiple studies have suggested that a nucleated cell dose below 1.5 to 2 x 107/kg results in an unacceptably high risk for graft failure. Only a minority of adult patients will have a suitably matched umbilical cord blood unit that contains more than 1.5 x 107 nucleated cells/kg. The second reason for inferior outcome of umbilical cord blood transplantation in adult patients is that in comparison to children, the conventional myeloablative bone marrow conditioning regimens are more toxic. This phase 1 protocol will use a potentially less toxic bone marrow conditioning regimen, followed by infusion of a combined umbilical cord blood graft that will provide the patient with a higher stem cell dose than can be given with a single umbilical cord blood infusion. The subjects will be conditioned with a TBI 13.5 Gy and fludarabine. Fludarabine pharmacokinetics will be measured and correlated with the kinetics of donor cell engraftment as well frequency of treatment-related toxicity. Following conditioning, up to two unrelated, partially matched umbilical cord blood grafts will be infused that will provide a minimum nucleated cell dose of 3 x 10e7/kg. The primary objective of this study is to measure the frequency of treatment-related toxicity and engraftment.
Ages Eligible for Study: | 14 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Non-Hodgkin's lymphoma or Hodgkin's disease:
Patients must have adequate function of other organ systems as measured by:
Pulmonary function tests demonstrating FVC and FEV1 of > or equal to 50% of predicted for age and DLCO
Exclusion Criteria:
United States, North Carolina | |
Duke University Health System | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Mitchell Horwitz, MD | Duke University Health System |
Responsible Party: | Duke University Health System, Department of Medicine, Cell Therapy Div. ( Mitchell Horwitz, MD ) |
Study ID Numbers: | 00009529 |
Study First Received: | January 7, 2008 |
Last Updated: | August 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00606437 History of Changes |
Health Authority: | United States: Institutional Review Board |
Umbilical Cord Blood Graft Stem Cell Transplantation |
Antimetabolites Precancerous Conditions Immunologic Factors Furosemide Leukemia Preleukemia Metaplasia Hodgkin Disease Lymphoma Dextrans Myelofibrosis Immunoproliferative Disorders Hematologic Diseases |
Hodgkin Lymphoma, Adult Myelodysplastic Syndromes Myeloproliferative Disorders Hodgkin's Disease Fludarabine monophosphate Immunosuppressive Agents Multiple Myeloma Myeloid Metaplasia Lymphatic Diseases Fludarabine Bone Marrow Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Antimetabolites Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Precancerous Conditions Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Leukemia Preleukemia Therapeutic Uses Lymphoma Hodgkin Disease Myelofibrosis Neoplasms by Histologic Type Immunoproliferative Disorders |
Immune System Diseases Hematologic Diseases Myelodysplastic Syndromes Myeloproliferative Disorders Fludarabine monophosphate Immunosuppressive Agents Pharmacologic Actions Myeloid Metaplasia Lymphatic Diseases Neoplasms Fludarabine Bone Marrow Diseases Lymphoproliferative Disorders Splenic Diseases |